secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001171843-22-003326
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Pharma Q1 net loss $8.3M; cash $62.9M; Phase 2 NSCLC trial planned
-------------------------------------------------------------------------

- Net loss $8.3M for Q1 2022 vs $11.6M in Q1 2021; R&D expenses down to $5.1M from $8.2M.
- Cash, cash equivalents and marketable securities $62.9M as of March 31, 2022 vs $69.5M at Dec 31, 2021.
- Plans Phase 2 randomized trial of mupadolimab + chemo in front-line NSCLC in 2022 with ~150 patients.
- Phase 1b/2 ciforadenant + ipilimumab/nivolumab in front-line RCC to start Q3 2022 via Kidney Cancer Consortium.
- Phase 1/1b CPI-818 (ITK inhibitor) continues enrolling T-cell lymphoma patients; data expected later 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184322003326/0001171843-22-003326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184322003326/f8k_050522.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-003326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer